Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prulifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prulifloxacin SCHEMBL13896543 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1699755 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL29540773 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL7060281 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL136641 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL13822719 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL28660626 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL9673724 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1231520 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL9674383 | 0.96 | LMNA (0.92) | LMNAPRKD3PIM1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354144-A1 | Crystals of quinolinecarboxylic acid derivative solvate | Nippon Shinyaku Co., Ltd. (JP) | 2011-08-10 | — | — | EP | claimed |
| US-7612205-B2 | Crystals of quinolinecarboxylic acid derivative solvate | NIPPON SHINYAKU CO., LTD. (JP) | 2009-11-03 | — | — | US | claimed |
| EP-1408034-B1 | Use of Quinolone and Quinolizinone derivatives as chemotherapeutic agents | SCHULZ & SCHLIMBACH GBR (DE) | 2007-08-08 | — | — | EP | claimed |
| US-20070149540-A1 | Crystals of quinolinecarboxylic acid derivative solvate | NIPPON SHINYAKY CO., LTD. (JP) | 2007-06-28 | — | — | US | claimed |
| EP-1626051-A1 | CRYSTALS OF QUINOLINECARBOXYLIC ACID DERIVATIVE SOLVATE | Nippon Shinyaku Co., Ltd. (JP) | 2006-02-15 | — | — | EP | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1408034-A1 | Use of Quinoline derivatives as antibacterial agents | Schulz & Schlimbach GbR (DE) | 2004-04-14 | — | — | EP | claimed |
| EP-1244434-A2 | USE OF CHEMOTHERAPEUTIC AGENTS | Schulz, Hans-Herrmann (DE) | 2002-10-02 | — | — | EP | claimed |
| WO-2001045679-A2 | USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT | SCHULZ HANS HERRMANN (DE) | 2001-06-28 | — | — | WO | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-4713056-A1 | DEVICE FOR PROVIDING CONTINUED BREATH GUIDANCE, METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE AND INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS/BREATH GUIDING | Pari Medical Holding GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712837-A1 | METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE, INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS FEEDBACK AND DEVICE FOR PROVIDING FEEDBACK GUIDANCE | Pari Medical Holding GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-12503718-B2 | Biomarker and treatment target for alcoholic hepatitis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4659255-A1 | MEDICAL EVALUATION METHOD, AEROSOL NEBULIZER AND MEDICAL EVALUATION SYSTEM | Pari Medical Holding GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-12263192-B2 | Compositions for management of disorders of the gastrointestinal tract | PANTHERYX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0627218-A1 | FAST SOLUBLE TABLET | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-12-07 | — | — | EP | disclosed |
| EP-0580861-A1 | CAPSULE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-02-02 | — | — | EP | disclosed |
| EP-0580860-A1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-02-02 | — | — | EP | disclosed |
| EP-0315828-B1 | QUINOLINECARBOXYLIC ACID DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1992-04-08 | — | — | EP | disclosed |